Logo Image

Authors

Aaron S. Mansfield MD, Tobias Peikert, MD
Latest Article

Potential Applications of Immune Checkpoint Blockade for Mesothelioma

Malignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.

Aarti S. Bhardwaj, MD
Latest Article

Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.

Abigail L. Stockham, MD
Latest Article

The Role of Radiation in the Management of Brain Metastases

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.

Adam Brufsky, MD, Pittsburgh
Adam I. Riker, MD
Latest Article

Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade

Adam M. Brufsky, MD, PhD, FACP, University of Pittsburgh
Adam M. Brufsky, MD, PhD, FACP, University of Pittsburgh School of Medicine
Adam M. Brufsky, MD, PhD, M University of Pittsburgh
Adam M. Brufsky, MD, PhD, University of Pittsburgh
Adam M. Brufsky, MD, PhD, University of Pittsburgh Cancer Institute
Adam M. Brufsky, MD, PhD, University of Pittsburgh School of Medicine
Adam M. Brufsky, MD, University of Pittsburgh
Adam M. Brufsky, MD, UPMC
Adan M. Brufsky, MD, PhD, Comprehensive Breast Cancer Center
Adi Diab, MD, University of Texas MD Anderson Cancer Center
Adil Daud, MD, University of California Medical Center
Adrienne Hill, DO
Latest Article

Impairment-Driven Cancer Rehabilitation Improves Survivors' Quality of Life

The lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.

Ahmad Awada, MD, PhD, Jules Bordet Institute
Ahmad Halwani, MD
Latest Article

It's Time to Tackle the Evidence Gap in Lymphoid Cancers

Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.

Ahmed A. Hussein Aly, MD, PhD
Latest Article

TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?

Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.

Ahmed Kaseb, MD, MD Anderson Cancer Center
Aileen M. Soper, BA
Latest Article

NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management

Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai
Ajai Chari, MD, Icahn School of Medicine, Mount Sinai
Ajay K. Gopal, MD, FACP, of Fred Hutch cancer Center
Ajay K. Gopal, MD, FACP

Ajay K. Gopal, MD, FACP, is the medical director for Hematology, Malignancies/Hematology, the clinical research director for the Lymphoma Program and an professor in the Clinical Research Division at Fred Hutch Cancer Center; professor of Hematology and Oncology in the Division of Hematology and Oncology at the University of Washington School of Medicine, and the Stephen Hans Petersdorf, MD, Endowed Chair in Cancer Care at the University of Washington Medicine, both located in Washington.

Latest Article

Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

Ajay V. Maker, MD, FACS
Latest Article

New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

Aju Mathew, MD, MPhil
Latest Article

Staying Afloat When the Floodgates Open

It is quite easy to be drowned in the rising floodwaters of hematology and medical oncology, especially when you start training.

Akhil Kumar, MD
Latest Article

Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review

In order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.

Akshat Jain, MD, MPH’15
Latest Article

International Hematology/Oncology Elective: A Unique Learning Experience

Although minor institution-specific variations exist, traditional fellowship programs in the United States are able to provide training in the sophisticated Western style of practice.

Al B. Benson III, MD, Northwestern